PSA Response After Each Cycle of Therapy for 3 Groups
| Group A | Group B | Group C | ||||||||||
| PSA response | First | Second | Third | All* | First | Second | Third | All* | First | Second | Third | All* |
| PR | 0/10 (0.0%) | 2/9 (22.2%) | 1/4 (25.0%) | 1/10 (10.0%) | 4/10 (40.0%) | 5/9 (55.5%) | 2/5 (40.0%) | 4/10 (40.0%) | 2/8 (25.0%) | 5/8 (62.5%) | 4/5 (80.0%) | 5/8 (62.5%) |
| Stable disease | 4/10 (40.0%) | 0/9 (0.0%) | 0/4 (0.0%) | 0/10 (0.0%) | 4/10 (40.0%) | 1/9 (11.1%) | 2/5 (40.0%) | 3/10 (30.0%) | 3/8 (37.5%) | 1/8 (12.5%) | 0/5 (0.0%) | 1/8 (12.5%) |
| PD | 6/10 (60.0%) | 7/9 (77.7%) | 3/4 (75.0%) | 9/10 (90.0%) | 2/10 (20.0%) | 3/9 (33.3%) | 1/5 (20.0%) | 3/10 (30.0%) | 3/8 (37.5%) | 2/8 (25.0%) | 1/5 (20.0%) | 2/8 (25.0%) |
↵* PSA response before and 8 wk after last cycle of treatment in all enrolled patients who had received at least 1 cycle of therapy.